Review
Hematology
Wilma Barcellini, Bruno Fattizzo
Summary: Warm autoimmune hemolytic anemia is a disease caused by increased destruction of red blood cells by IgG autoantibodies, with complex pathogenic mechanisms and unpredictable prognosis. Treatment options include steroids, splenectomy, immunosuppressants, and rituximab, but challenges exist in choosing and managing these therapies.
Review
Pharmacology & Pharmacy
Zhengrui Xiao, Irina Murakhovskaya
Summary: AIHA is a rare autoimmune disorder characterized by the destruction of red blood cells mediated by autoantibodies, presenting challenges in treatment. Traditional first-line therapies have associated adverse effects and treatment failures, with high rates of relapse. Some patients are refractory to available treatments, leading to the importance of novel therapies.
Review
Chemistry, Medicinal
Hsu-En Huang, Ko-Ming Lin, Jing-Chi Lin, Yu-Ting Lin, Hsiao-Ru He, Yu-Wei Wang, Shan-Fu Yu, Jia-Feng Chen, Tien-Tsai Cheng
Summary: Danazol therapy is an effective option for patients with refractory AIHA and ITP. In a 6-month observational study, 100% of AIHA patients and 75% of ITP patients achieved treatment response. Responders were able to reduce the dose of glucocorticoids and discontinue immunosuppressants.
Article
Immunology
Flavia Dei Zotti, Annie Qiu, Francesca La Carpia, Chiara Moriconi, Krystalyn E. Hudson
Summary: Autoimmune hemolytic anemia is a severe disease with limited treatment options and challenges in RBC transfusions due to autoantibodies against ubiquitous RBC antigens.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pathology
Jeremy W. Jacobs, Thomas C. Binns, Elizabeth Abels, Juan J. Silva Campos, Ragaa Elkabbani, Anna Kress, Nataliya Sostin, Christopher A. Tormey
Summary: In this study, 3 cases of red blood cell (RBC) autoantibodies with unusual apparent antigenic specificity were described, and the testing methodology and implications of these findings were discussed. All immunohematologic testing was performed using standardized and validated methods and reagents. These 3 cases complement the minimal literature regarding warm autoantibodies with unusual antigenic specificity and their potential to mediate clinically significant hemolysis.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Review
Hematology
Bruno Fattizzo, Wilma Barcellini
Summary: In this review article, a critical analysis is provided on recent reports evaluating innovative therapies for warm type autoimmune hemolytic anemia (wAIHA). The efficacy and limitations of different drugs, as well as ongoing clinical trials, are discussed.
TRANSFUSION MEDICINE REVIEWS
(2022)
Article
Rheumatology
Lennard Ostendorf, Marie Burns, Dimitrios Laurin Wagner, Philipp Enghard, Kerstin Amann, Henrik Mei, Kai-Uwe Eckardt, Evelyn Seelow, Adrian Schreiber
Summary: Daratumumab, an anti-CD38 antibody, was found to be safe and effective in treating treatment-refractory AAV. Two patients with severe renal and pulmonary manifestations showed significant clinical and immunological improvements after receiving daratumumab treatment.
Article
Clinical Neurology
Franziska Scheibe, Lennard Ostendorf, Harald Pruess, Helena Radbruch, Tom Aschman, Sarah Hoffmann, Igor-Wolfgang Blau, Christian Meisel, Tobias Alexander, Andreas Meisel
Summary: This study retrospectively examined the efficacy of daratumumab in patients with antibody-mediated autoimmune diseases. The results showed that daratumumab treatment led to significant clinical improvement and reduction in autoantibody production.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Hematology
Brandon Calhoun, Andrew Moore, Andrew Dickey, D. Matthew Shoemaker
Summary: This study describes two cases of warm autoimmune hemolytic anemia (AIHA) caused by systemic loxoscelism. The patients developed symptomatic anemia after being bitten by a brown recluse spider, and were subsequently diagnosed with warm AIHA. Treatment with corticosteroids, aggressive intravenous fluid hydration, and packed red blood cell transfusion led to clinical improvement and eventual discharge.
Review
Hematology
Jeremy W. Jacobs, Cristina A. Figueroa Villalba, Garrett S. Booth, Jennifer S. Woo, Laura D. Stephens, Brian D. Adkins
Summary: Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia that is often overlooked and challenging to diagnose due to the complicated testing methods required. A systematic review of reported cases revealed that PCH most commonly occurs in children with a preceding viral infection, and corticosteroid use is frequent but potentially ineffective. The presence of complement and absence of IgG bound to red blood cells is the most common DAT result, although other findings were observed in a third of cases.
Article
Medicine, General & Internal
Fadi Tahhan, Brandon Huynh, Prissilla Xu
Summary: Autoimmune hemolytic anemia (AIHA) is characterized by hemolysis, with cold agglutinin disease (CAD) and warm autoimmune hemolytic anemia (wAIHA) being the two major forms. CAD is complement dependent, whereas wAIHA is partially complement-mediated. Sutimlimab-jome is the only FDA-approved monoclonal antibody for CAD treatment, and it has shown efficacy in treating severe treatment-refractory wAIHA as well.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Review
Hematology
Abdelaziz Mohamed, Mohammed Alkhatib, Awni Alshurafa, Halima El Omri
Summary: This case report describes a 69-year-old female patient with refractory Cold Agglutinin Disease (CAD) who did not respond to standard treatment options. The report shows that the combination therapy of daratumumab and erythropoietin led to a significant response in controlling the disease.
Article
Pediatrics
Jiacheng Li, Xizhou An, Ximing Xu, Li Xiao, Yang Wang, Yao Zhu, Lan Huang, Kainan Zhang, Xinyuan Yao, Weijia Yi, Jiebin Qin, Jie Yu
Summary: This study aimed to identify risk indicators for early recurrence of primary warm-antibody autoimmune hemolytic anemia (w-AIHA) in children and construct an effective recurrence risk assessment model. The results showed that blood type O, low mean corpuscular hemoglobin concentration (MCHC), and high reticulocyte count (Ret) were risk indicators for early recurrence of pediatric primary w-AIHA.
FRONTIERS IN PEDIATRICS
(2022)
Article
Biochemistry & Molecular Biology
Dario Roccatello, Roberta Fenoglio, Ilaria Caniggia, Joelle Kamgaing, Carla Naretto, Irene Cecchi, Elena Rubini, Daniela Rossi, Emanuele De Simone, Giulio Del Vecchio, Martina Cozzi, Savino Sciascia
Summary: This study presents a case series of six patients with refractory lupus nephritis who were treated with an off-label anti-CD38 monoclonal antibody. Five patients achieved complete or partial renal responses after 12 months of follow-up. These findings suggest that daratumumab monotherapy shows promise as a potential treatment for refractory lupus nephritis.
Article
Medicine, General & Internal
Takakazu Higuchi, Takao Hoshi, Mitsuru Toriyama, Atsuko Nakajima, Kosuke Haruki
Summary: Thrombotic complications are rare in Japanese WAIHA patients, suggesting that these patients do not have a particularly increased risk of thrombosis due to WAIHA. The indication for VTE prophylaxis should be determined individually, taking into account other risks.
Letter
Hematology
Ankur Jain, J. M. Khunger, Siddharth Kapahtia, Pooja Prasad, D. K. Gupta, Sumita Chaudhry
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2019)
Letter
Hematology
Ankur Jain, Sumita Saluja, Sumita Chaudhry, D. K. Gupta
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2019)
Letter
Hematology
Ankur Jain, Sumita Saluja, Sumita Chaudhry, D. K. Gupta
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2019)
Letter
Hematology
Ankur Jain, Pooja Prasad, Sumita Chaudhry, D. K. Gupta, Sumita Saluja
EUROPEAN JOURNAL OF HAEMATOLOGY
(2019)
Editorial Material
Hematology
Ankur Jain
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2020)
Letter
Hematology
Ankur Jain
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2020)
Article
Hematology
Ankur Jain, Alka Khadwal, Man Updesh Singh Sachdeva, Praveen Bose, Deepesh Lad, Shalmoli Bhattacharya, Gaurav Prakash, Pankaj Malhotra, Neelam Varma, Subhash Varma
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Oncology
Ankur Jain, Karthik Ramasamy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2020)
Article
Hematology
Ankur Jain, Alka Khadwal, Man Updesh Singh Sachdeva, Praveen Bose, Deepesh Lad, Shalmoli Bhattacharya, Gaurav Prakash, Pankaj Malhotra, Neelam Varma, Subhash Varma
Summary: Endogenous pre-HSCT MSC counts were found to be positively correlated with post-HSCT infectious complications, but not with engraftment and mucositis. This suggests that MSC levels pre-HSCT may influence infections and treatment outcomes post-transplantation.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2021)
Letter
Hematology
Pankaj Malhotra, Hari Prasad, Ankur Jain, Vivek Gupta, Neelam Varma
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Letter
Medicine, General & Internal
Ankur Jain
AMERICAN JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Ankur Jain, Sumita Chaudhry, Monica Sharma
AMERICAN JOURNAL OF MEDICINE
(2022)
Editorial Material
Hematology
Ankur Jain
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Cardiac & Cardiovascular Systems
Rohan Magoon, Ankur Jain
HEART LUNG AND CIRCULATION
(2022)
